Ideaya Biosciences Inc (IDYA)
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
📉 **NEGATIVE** • Medium confidence analysis (69%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General